Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.58 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.58 |
| ▸ | ERN1 | O75460 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | GALR3 | O60755 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5514174 | 0.79 | ESR1 (0.72) | ESR1ESR2CYP1A2HSD17B1HSD17B2 | |
| SCHEMBL6356696 | 0.79 | ERN1 (0.59) | ESR1ESR2ERN1MAPTMEN1 | |
| SCHEMBL50832 | 0.79 | ESR1 (0.61) | ESR1ESR2ERN1MAPTMEN1 | |
| SCHEMBL993774 | 0.79 | ERN1 (0.59) | ESR1ESR2ERN1MAPTMEN1 | |
| SCHEMBL2840122 | 0.79 | CYP2A6 (0.43) | ESR1ESR2ERN1MAPTMEN1 | |
| SCHEMBL29365143 | 0.79 | ERN1 (0.59) | ESR1ESR2ERN1MAPTMEN1 | |
| SCHEMBL2305904 | 0.76 | ESR1 (0.58) | ESR1ESR2ERN1MAPTMEN1 | |
| SCHEMBL5343236 | 0.76 | ESR2 (0.58) | ESR1ESR2ERN1MAPTMEN1 | |
| SCHEMBL31444547 | 0.76 | ESR2 (0.58) | ESR1ESR2ERN1MAPTMEN1 | |
| SCHEMBL26205109 | 0.76 | ERN1 (0.56) | ESR1ESR2ERN1MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445367-B1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3445367-B1 | HEPATITIS C VIRUS INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO LTD (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO LTD (CN) | 2023-06-01 | — | — | US | disclosed |
| WO-2022015624-A1 | SUBSTITUTED DIHYDROPYRAZINEDIONES AS MODULATORS OF THE NMDA RECEPTOR | SCHRÖDINGER, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| WO-2022015624-A1 | SUBSTITUTED DIHYDROPYRAZINEDIONES AS MODULATORS OF THE NMDA RECEPTOR | SCHRÖDINGER, INC. (US) | 2022-01-20 | — | — | WO | disclosed |
| WO-2021108974-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | GANNEX PHARMA CO., LTD (CN) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021109713-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | GANNEX PHARMA CO., LTD. (CN) | 2021-06-10 | — | — | WO | disclosed |
| WO-2021109712-A1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | GANNEX PHARMA CO., LTD. (CN) | 2021-06-10 | — | — | WO | disclosed |
| US-10787441-B2 | Hepatitis C virus inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-27 | — | — | US | disclosed |
| CN-101056635-A | Niacin receptor agonists, compositions containing such compounds and methods of treatment | MERCK & CO INC (US) | 2007-10-17 | — | — | CN | disclosed |
| EP-1809284-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck & Co., Inc. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2006052555-A2 | NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
| US-6894200-B2 | Synthesis of vicinal difluoro aromatics and intermediates thereof | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2005-05-17 | — | — | US | disclosed |
| EP-1445245-A1 | Synthesis of vicinal difluoro aromatics and intermediates thereof | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20030149315-A1 | Synthesis of vicinal difluoro aromatics and intermediates thereof | VERSUM MATERIALS US, LLC | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165843-A1 | USE AND PHARMACEUTICAL COMPOSITION OF PHENYLISOXAZOLYL METHYLENE-NAPHTHALENE-ETHER DERIVATIVES | VIM, CYP3A7, HAVCR2 | ESR1 2052/4885ESR2 1707/4885ERN1 2380/4885 |
| US-10787441-B2 | Hepatitis C virus inhibitors | HAVCR2, FABP1, SLC10A1 | ESR1 3596/4885ESR2 2555/4885ERN1 343/4885 |
| US-20030149315-A1 | Synthesis of vicinal difluoro aromatics and intermediates thereof | HAAO, PAH, PFAS | ESR1 3902/4885ESR2 3363/4885ERN1 2722/4885 |
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | ESR1 2624/4885ESR2 1401/4885ERN1 3446/4885 |
| US-20070299101-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | LDLR, APOB, FFAR1 | ESR1 1373/4885ESR2 1761/4885ERN1 3126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.